2020 VISTA is the Website for LPBI Group’s Ten Health Care Contents Asset Classes prospected for technology ownership transfer and monetization
9/25/2020
1.0 & 2.0 LPBI Group’s Team
- Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0
- Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences
- Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology
- Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group
- Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author
- Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases
- Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery
- Gail S. Thornton, PhD(c), Contributing Editor, Author and Medical Writer, Marketing Communications
- Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML
8/19/2020
An UPDATE Shared with ALL
We launched on 3/14/2020 the Coronavirus PORTAL https://pharmaceuticalintelligence.com/coronavirus-portal/ which covers 8 topics:
- Breakthrough News Corner
- Development of Medical Counter-measures for 2019-nCoV, CoVid19, Coronavirus
- An Epidemiological Approach Stephen J. Williams, PhD and Aviva Lev-Ari, PhD, RN Lead Curators – e–mail Contacts: sjwilliamspa@comcast.net and avivalev-ari@alum.berkeley.edu
- Community Impact Stephen J. Williams, PhD and Irina Robu, PhD Lead Curators – e–mail Contacts: irina.stefania@gmail.com and sjwilliamspa@comcast.net
- Economic Impact of The Coronavirus Pandemic Dr. Joel Shertok, PhD Lead Curator – e–mail Contact: jshertok@processindconsultants.com
- Voices of Global Citizens: Impact of The Coronavirus Pandemic, Gail S. Thornton, M.A. Lead Curator – e–mail Contact: gailsthornton@yahoo.com
- Diagnosis of Coronavirus Infection by Medical Imaging and Cardiovascular Impacts of Viral Infection, Aviva Lev-Ari, PhD, RN Lead Curator e-mail contact: avivalev-ari@alum.berkeley.edu
- Key Opinion Leaders Followed by LPBI Aviva Lev-Ari, PhD, RN and Dr. Ofer Markman, PhD Lead Curators e-mail contacts: oferm2015@gmail.com and avivalev-ari@alum.berkeley.edu
That effort took 2 months of most intensive work on my part.
STATEMENT
- The economic impact of of the Pandemic DOES HAVE A NEGATIVE EFFECT ON THE M&A MARKET
- In the INTERIM awaiting for more favorable conditions on the market
- we invested in INTERNAL development of IP
We launched FOUR additional PORTALS:
- Artificial Intelligence in Genomics & Cancer
https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/
- 2020 Summer Internship Portal
https://pharmaceuticalintelligence.com/2020-summer-internship/
- Knowledge PORTALS System (KPS) @LPBI
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
- 2021 Medical Text Analysis (NLP)
https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
- As an ADJUSTMENT for submitting the documentation to the Investment Banker in 10/2020 vs the original plan 4/2020, we are working on
- The Plan for 2021 – 2025. It involves six new strategies: TNS #1,2,3,4,5,6
TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market
Phase 1: Natural Language Processing(NLP) – 24 months FREE Microsoft AZURE for Health
Phase 2: Piloting the Proof of Concept on 4 of LPBI BioMed 16 volumes:
- Cancer, Volume 1 & 2 and Genomics, Volume 1 & 2
Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:
TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End
TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA
TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio [SEE New Yorker] – HAS POTENTIAL
TNS #5: Joint venture with Dr. Nir for Drug Discovery:
TNS #6: e-Books Translations into Japanese, Spanish, Russian
These are two distinctive entities
2.0 LPBI, 1/2021 – 12/2025 – TNS #1,2,3,4,5,6, above. Executive Summary
https://pharmaceuticalintelligence.com/leaders-in-pharmaceutical-business-intelligence/
1.0 LPBI, 4/2012 – 12/2020 – Executive Summary
https://pharmaceuticalintelligence.com/home-website-front-page/
Cumulative Revenue Potential PREDICTION of Journal Articles: Under Two Growth Assumption Regimes and Two Prediction Models
RED & BLUE Lines
A. Rate of Articles published in 2021-2025 is trending 2017, 2018, 2019, 2020
RED Line – A Marked Point Process Model: $48MM for Journal Valuation
BLUE Line – A Conservative Assumption-based Growth Prediction (Joel)
vs
BROWN & GREEN Lines
B. No New Articles after 12/2020 will be published
BROWN Line – A Marked Point Process Model – Assuming Last article published on 12/31/2020
GREEN Line – A Conservative Assumption-based Growth Prediction (Joel) – Assuming Last article published on 12/31/2020
Data Source:
WordPress.com Web Statistics of 1.8 Million Views of 6,000 Scientific Articles, 6/30/2020
[for the Annual 2020 data: the first 6 months x2].
4/2012 – 12/2020 – ACTUALS
2021 – 2025 – FORECAST 
Our portfolio of Intellectual Property (IP) include TEN asset classes
| Asset Classes | Type | Quantity |
|
Asset Class I |
The Journal
9/25/2020 Views 1,829,736
|
5,924 articles on 9/25/2020 Valuation [$XXM] done by Joel on Alex WP Data ____________ |
|
Asset Class II |
BioMed e-Series | 16 volumes
Valuation [$5M] done by Joel & Aviva August 2020 121,547 page downloads in total on 8/31/2020. This number represents the equivalent of 52 books to have been sold [KENP to Book] ____________ |
|
Asset Class III |
eProceedings | 60 events
Valuation [$1.4M] done by Dr. Williams & Aviva ____________ |
|
Asset Class IV |
Platform, composition of methods and workflows for the content creation of scientific curations. See Platform:
https://pharmaceuticalintelligence.com/coronavirus-portal/
https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/
https://pharmaceuticalintelligence.com/2020-summer-internship/
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
|
$6MM |
|
Asset Class V |
Gallery of Biological Images in use in Articles and Books | 5,100 Biological images in the Journal’s Media Gallery
____________ |
|
Asset Class VI |
Team of Experts
See Platform: • Knowledge Platform System (KPS) https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/ |
BIOs Final Improvement Team (FIT)
$3MM
____________ |
|
Asset Class VII |
Royalties on BioMed e-Series:Page downloads, Book borrowings and Book sale | August 2020 121,547 page downloads in total on 8/31/2020. This number represents the equivalent of 52 books to have been sold [KENP to Book]
____________ |
|
Asset Class VIII |
Subscribers to the Website |
2,549 on 8/18/2020
____________ |
|
Asset Class IX |
INTANGIBLE ASSETS & Intrinsic Value = Good Will | TBD |
|
Asset Class X |
e-VOICES PODCASTING – Audio Library
e-VOICES Podcasting, 2019 – 2021 |
Shared FREE like industry standard |
We estimate revenue potential of each entity to be
~~ $XX Million for 1.0 LPBI [Above Ten IP Asset Classes]
- Graph above present the Valuation of IP Asset Class I
~~ $XX Million for 2.0 LPBI [Excel Sheet for Financial Projection was developed in 8/2020]
~~ $ XXX Million for 1.0 LPBI plus 2.0 LPBI
The feedback that we will get from the Investment Banker will guide the TIMING and the Strategy
- ALL ACTIVE Member of the Final Improvement Team (FIT) on record for the EXIT will be in constant communication regarding all of the above
- Personal PORTAL for each member of FIT is displayed on https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
- Meg Baker is considering a collaboration in the JOINT VENTURE (LPBI X%) and Dr. Raphael Nir (7X%) on Galectins & Synthetic Biology in Drug Discovery
- Our Podcast Library is growing – See Table, below
Development Plan for e-VOICES Podcasting, 2019 – 2021*
https://pharmaceuticalintelligence.com/audio-podcasts/
| Podcast Interviewer | INTERVIEWEE(S) | Subject | Date | Audio/Video/
Narrator |
| Gail S. Thornton | Dr. Stephen J. Williams, Dr. Irina Robu & Dr. Aviva Lev-Ari | 3D BioPrinting in Medicine | 5/2019 | Audio |
| Gail S. Thornton | Prof. Feldman | Evolution Biology and Population Genetics | 3/17/2020 | Audio |
| Gail S. Thornton | Dr. Larry H. Bernstein, MD, FCAP | Life Memoirs in Clinical Pathology Told | 8/2020 | Audio
Narrator: Dr. S.J. Williams |
| Gail S. Thornton | Dr. Justin D. Pearlman, MD, PhD | Cardiac Imaging – Evolution of Diagnostic Methods | 4Q 2020 | Audio |
| Gail S. Thornton | Dr. Raphael Nir | From Big Pharma to Biotech Entrepreneurship | 2021 | Audio |
| Gail S. Thornton | Dr. Meg Baker | GlycoBiology in Practice | 2021 | Audio |
| Gail S. Thornton | Dr. Ofer Markman | Memories of
Procognia |
2021 | Audio |
*Dr. Williams and Aviva – will have their Podcasts in 2021.
DETAILS about IP Asset Class I: LPBI Journal, IP Asset Class II: BioMed e-Series and IP Asset Class III: Biotech & Medical Conference e-Proceedings and Tweet Collections
Our VAST intellectual property (IP) portfolio includes three asset classes:
-
IP Asset Class I: LPBI Journal
+1.8Million eReaders, +5900 scientific articles, +700 categories of research
-
IP Asset Class II: BioMed e-Series
16 Volumes in Medicine
What make our e-Books UNIQUE: An Example
Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology. Published on 12/28/2019
- No other book covers the same topics in a single volume. In terms of synergy, this book combines:
1. Content curation in article format with embedded videos and audio podcasts
2. Conference e-Proceedings based on real-time coverage by the authors and editors of this book.
3. Archived tweets of quotes from speakers at leading Biotech conferences, posted in real-time by the same authors- It integrates in a single volume four distinct perspectives: (a) basic science, (b) technologies & methodologies, (c) clinical aspects, and (d) business and legal aspects.
- The material in this book represents the scientific frontier in Biological Sciences and Medicine related to the Genomics aspects of Disease Onset. It addresses:
1. All aspects of life: the Cell, the Organ, the Human Body and Human Populations
2. All methodologies of genomic data analysis: Next Generation Sequencing, Gene Editing, AI, Single Cell Genomics, Evolution Biology Genomics, Simulation Modeling in Genomics, Genotypes and Phenotypes Modeling, measurement of Epigenomics effects on disease, and developments in Pharmaco-GenomicsArtificial Intelligence in Medicine is covered in Part 3 of the e-Book. 3.1 to 3.5 represent the frontier in this emerging field:
3.1 The Science
3.2 Technologies and Methodologies
3.3 Clinical Aspects
3.4 Business and Legal
3.5 Latest in Machine Learning (ML) Algorithms harnessed for Medical Diagnosis: Pattern Recognition & Prediction of Disease Onset
- No other book incorporates 74 e-Proceedings created in real time by the Book’s authors and editors
- No other book incorporates four collections of Tweets representing quotes from speakers at global leading conferences on Genomics
- No other book has 13 locations of Videos and Audio Podcasts that serve to enrich the e-Reader’s experience
- No other book has 326 articles on the topics included in the Book’s title: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology
-
IP Asset Class III: Biotech & Medical Conference e-Proceedings
Corpus of 70 events covered in real time yielding 60 e-Proceedings and 36 Tweet Collections
OTHER ASSET CLASSES: IV, V, VI, VII, X
- Asset Class IV is the platform, composition of methods and workflows for the content creation of scientific curations
- Asset Class V is a Gallery of 5,100 images used in the articles and books
- Asset Class VI is the Team of Experts
- Asset Class VII are the Royalties on BioMed e-Series:
- e-Book age down loads,
- e-Book borrowings and
- e-Book sale
- Asset Class X are the e-Voices Podcasting – Audio Podcasts Library https://pharmaceuticalintelligence.com/audio-podcasts/
Asset List showing Value:
@@@@@ TANGIBLE ASSETS:
1. The Journal has 1,829,736 eReaders on 9/25/2020 – ASSET CLASS I
— It has +5900 articles
— It demonstrates > 7500 comments by Scientists for +5900 articles
— It has +10K tags counted by the computer
— It has +700 categories of research in SIX disciplines among them the most complex are
- Cell signaling
- ATP
- Autophage
- Computational Biology and NGS
- Cardiac imaging
- Endosome
- Liposomes
— It has 2,549 subscribers on 8/18/2020
2. The BioMed e-Series – ASSET CLASS II
Royalties structure:
– 121,547 page downloads in total on 8/31/2020
– x book borrowing
– y book sale – suppressed by Unlimited Prima Membership: READ FOR FREE and Pay per view
– 65% of book sales revenues is retained by Amazon
3. e-Proceedings and Activity on Twitter.com – ASSET CLASS III
- LPBI is the One and only e-Proceedings generator at end of Conference by one-Click
- The #WMIF19 Influencers via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19– By Mentions and By Tweets Ranked #4: @pharma_BI and Ranked #2: @AVIVA1950, respectively. Ranked #3 via @NodeXL Betweenness Centrality http://bit.ly/2KB6cPN
@@@@@ INTANGIBLE ASSETS equal e-Reputations
A. Institutions following @AVIVA1950 and @pharma_BI include the marque organizations as follows:
- TECHNION
- WEIZMANN INSTITUTE
- HEBREW UNIV
- PARTNERS INNOVATIONS: MGH & BWH
- BROAD INSTITUTE @MIT & @Harvard
- Bayer US
- PhRMA
- Keck Medicine of USC
- Intermountain Cancer
- MassBio
- Hadasit Bio Holdings
- BioWorld
- Bell Labs
- BCM_CVRI
- MIT Spectrum
- TED Talks
B. LPBI’s Founder is followed by 500 CEOs 200 CEOs in Biotech & Pharma on LinkedIn and
C. LPBI’s Founder has ~7300 followers 1st level connection on LinkedIn.
Distribution of 1st level LinkedIn connection by Industry
| Chemicals | 2366 |
| Pharmaceuticals | 919 |
| Biotechnology | 841 |
| Oil & Energy | 664 |
| Staffing and Recruiting | 218 |
| Management Consulting | 218 |
| Research | 207 |
| Information Technology and Services | 198 |
| Environmental Services | 183 |
| Plastics | 171 |
| Food & Beverages | 137 |
| Marketing and Advertising | 115 |
| Human Resources | 96 |
| Food Production | 93 |
| Financial Services | 92 |
D. LPBI’s Founder is bestowed by >1000 endorsements
@@@@ LPBI Group’s Social Media Presence in 2020
Our Social Media Presence in 2020 is by two handles on Twitter.com
@pharma_BI
Official handle of my Venture: Leaders in Pharmaceutical Business Intelligence (LPBI) Group,
Boston, MA, NJ, CA, PA, ME, DE, India, Israel & Canada
@AVIVA1950
Personal account of Aviva Lev-Ari, PhD, RN – LPBI Group’s Founder
2019 World Medical Innovation Forum on AI in Medicine – Aviva’s rankings as Influencer
- The #WMIF19 Influencers via @symplur‘s #HealthcareHashtags http://bit.ly/WMIF19– By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN
- For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets
Follow the links
- Executive Summary
- Opportunities Map in the Acquisition Arena
- Dynamic Contents for LPBI Group’s PowerPoint Presentation
- Detailed Technology Description
- Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences
- Top Authors by Number of eReaders Views
- Top Articles by Number of e-Readers for All Days ending 2019-02-17
- LPBI Group’s Social Media Presence
- Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes
- Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series
- Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class
- Financial Advisory & Legal Advisory Providers: US & Israel
- Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group
- FIT Members Contribute to Opportunities Map
- FINAL IMPROVEMENT TEAM (FIT): Definition of Active, Lapsing of Active Status, COMPs Formulas
- Mostly HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019
- LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019
- FIT members – Who works on WHAT?
- Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
- MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by
- JOURNAL Statistics on 2/24/2019
- Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019
- Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers
- REACH – Two Handles on Twitter.com @AVIVA1950 @pharma_BI
- 2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis
- Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN
- 2020/2021 LPBI Plan for IT Projects & Reseach Projects – LPBI’s TASKS for Research Assistants & Associates
- LPBI’s Pipeline Map: A Positioning Perspectives – An Outlook to the Future from the Present
- WHAT ARE LPBI Group’s NEEDS in June 2019: Aviva’s BOLD VISION on June 11, 2019
- For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers] https://analytics.twitter.com/user/AVIVA1950/tweets
- The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation
- e-Proceedings and Tweet Collections per Conference, 2013-2020, # Views=Downloads x $100: Real Time Coverage of 60 Events by ALA & SJW
- Institutional versus Personal: Statistical Analysis of Two Twitter Handles – @pharma_BI (LPBI Group’s Official) and @AVIVA1950 (LPBI Group’s Founder’s Personal) – Comparative Analysis of Followers and The Followers of these two Handles’ Followers
Our Team
- Aviva Lev-Ari, PhD, RN, Director and Founder
- Members of the Board
- Senior Editors
- Experts, Authors, Writers (EAWs)
- Business Development & Private Equity Investment
- Scientific Delegation Members & Patent Holders
- Inventors: Biologics
- Inventors: Medical Devices
- Research Assistants
- Research Associates
1.0 & 2.0 LPBI Group’s Team
- Aviva Lev-Ari, PhD, RN, Founder, LPBI Group: 1.0 & 2.0
- Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences
- Stephen J. Williams, Member of the Board, Chief Scientific Officer, Senior Editor, PhD Pharmacology, BSc Toxicology
- Joel Shertok, PhD, Member of The Board, Business Development and Process Designer of a Global AI-based External Relations Prospecting System for LPBI Group
- Justin D. Pearlman, MD, PhD, FACC – Scientific Expert & Key Opinion Leader on Cardiovascular Diseases, Cardiac Imaging & Complex Diagnosis in Cardiology: Senior Editor & Author
- Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases
- Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery
- Gail S. Thornton, PhD(c), Contributing Editor, Author and Medical Writer, Marketing Communications
- Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML
This page has the following sub pages.
- Executive Summary
- Opportunities Map in the Acquisition Arena
- Dynamic Contents for LPBI Group’s PowerPoint Presentation
- Detailed Technology Description
- Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences
- Top Authors by Number of e-Readers Views as of 2020-06-02
- Top Articles by Number of e-Readers for All Days ending 2020-06-02
- LPBI Group’s Social Media Presence
- Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes
- Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series
- Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class
- Financial Advisory & Legal Advisory Providers: US & Israel
- Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group
- Final Improvement Team (FIT) Members Contribute to Opportunities Map & Define LPBI Uniqueness
- FINAL IMPROVEMENT TEAM (FIT): Definition of Active, Lasping of Active Status, COMPs Formulas
- HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019
- LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019
- Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950
- MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by
- FIT members – Who works on WHAT?
- Institutional versus Personal: Statistical Analysis of Two Twitter Handles – @pharma_BI (LPBI Group’s Official) and @AVIVA1950 (LPBI Group’s Founder’s Personal) – Comparative Analysis of Followers and The Followers of these two Handles’ Followers
- JOURNAL Statistics from Inception, Data retrieved on 2/24/2019
- e-Proceedings and Tweet Collections per Conference, 2013-2020, # Views = Downloads x $100: Real Time Coverage of 60 Events by ALA & SJW
- Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019
- Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers
- REACH – Two Handles on Twitter.com @AVIVA1950 @pharma_BI
- 2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis
- Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN
- LPBI’s Pipeline Map: A Positioning Perspectives – An Outlook to the Future from the Present
- WHAT ARE LPBI Group’s NEEDS in June 2019: Aviva’s BOLD VISION on June 11, 2019
- 2020/2021 LPBI Plan for IT Projects & Reseach Projects – LPBI’s TASKS for Research Assistants & Associates
2012pharmaceutical
Aashir Awan, Phd
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Daniel Menzin
Dror Nir
dsmolyar
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22